Septerna (NASDAQ:SEPN) Director Alan Ezekowitz Sells 81,820 Shares of Stock

Septerna, Inc. (NASDAQ:SEPN – Get Free Report) Director Alan Ezekowitz sold 81,820 shares of the stock in a transaction on Wednesday, November 11th. The stock was sold at an average price of $48.09, for a total value of $3,934,723.80. Following the completion of the sale, the director directly owned 35,600 shares in the company, valued at approximately $1,712,004. This represents a 69.68% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Septerna Stock Performance

Shares of SEPN traded up $0.74 during trading hours on Friday, hitting $42.60. The company had a trading volume of 337,791 shares, compared to its average volume of 421,986. The stock has a market capitalization of $2.03 billion, a price-to-earnings ratio of -33.02 and a beta of 2.20. The firm has a fifty day moving average price of $40.46 and a 200-day moving average price of $33.12. Septerna, Inc. has a 52-week low of $19.69 and a 52-week high of $53.34.

Septerna (NASDAQ:SEPN – Get Free Report) last released its quarterly earnings data on Monday, November 9th. The company reported ($0.57) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.42) by ($0.15). Septerna had a negative net margin of 61.29% and a negative return on equity of 14.98%. The business had revenue of $18.88 million during the quarter, compared to the consensus estimate of $20.78 million. Research analysts anticipate that Septerna, Inc. will post -1.45 earnings per share for the current fiscal year.

Analysts Set New Price Targets

SEPN has been the topic of a number of research analyst reports. HC Wainwright upped their price target on Septerna from $40.00 to $60.00 and gave the company a “buy” rating in a report on Wednesday, August 12th. JonesTrading lifted their price objective on Septerna from $43.00 to $62.00 and gave the stock a “buy” rating in a report on Thursday, August 13th. Raymond James Financial reissued a “strong-buy” rating and issued a $49.00 target price on shares of Septerna in a research report on Tuesday, August 11th. Wells Fargo & Company upped their target price on shares of Septerna from $50.00 to $61.00 and gave the company an “overweight” rating in a research note on Wednesday, November 4th. Finally, Stifel Nicolaus raised their price target on shares of Septerna from $49.00 to $60.00 and gave the company a “buy” rating in a report on Tuesday. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $56.44.

Check Out Our Latest Research Report on SEPN

Key Septerna News

Investors following SEPN have been watching these news items:

Hedge Funds Weigh In On Septerna

Several hedge funds and other institutional investors have recently modified their holdings of the company. Sterling Capital Management LLC grew its holdings in shares of Septerna by 215.0% in the third quarter. Sterling Capital Management LLC now owns 630 shares of the company’s stock worth $25,000 after acquiring an additional 430 shares during the period. Mirae Asset Global Investments Co. Ltd. bought a new position in Septerna in the third quarter valued at about $93,000. Covestor Ltd lifted its holdings in Septerna by 19.0% in the third quarter. Covestor Ltd now owns 2,526 shares of the company’s stock valued at $98,000 after acquiring an additional 403 shares during the period. The Manufacturers Life Insurance Company bought a new position in Septerna in the second quarter valued at about $211,000. Finally, State Board of Administration of Florida Retirement System purchased a new position in Septerna in the third quarter worth about $232,000.

About Septerna

(Get Free Report)

Septerna is a clinical-stage biotechnology company developing medicines that target G protein-coupled receptors (GPCRs), a large family of proteins involved in many biological processes. The company is based in South San Francisco, California. Its discovery platform is designed to identify drug candidates that act on GPCRs, including targets that have been difficult to address with conventional drug-development approaches. Septerna is advancing candidates for endocrine, metabolic and other disease areas, with an emphasis on small-molecule medicines.

Featured Articles

Insider Buying and Selling by Quarter for Septerna (NASDAQ:SEPN)

Receive News & Ratings for Septerna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Septerna and related companies with MarketBeat.com's FREE daily email newsletter.